The Nanotechnology Characterization Laboratory (NCL) accelerates the development of nanotechnology for basic and applied cancer research. It is a national resource for cancer researchers to test nanotechnologies intended for cancer therapies and diagnostics. The NCL reduces suffering and death from cancer by accelerating the transition of basic nanoscale particles and devices into clinical applications.
The lab has characterized more than 360 nanomedicine products for researchers worldwide, and it has partnered with several pharmaceutical companies for nanotech reformulation and characterization efforts.
Through an application process, NCL offers preclinical characterization services to investigators who have developed promising nanotechnology-based cancer treatments. Once accepted, all characterization is performed at no charge to the submitting investigator.
NCL uses a three-tiered assay cascade to thoroughly characterize each nanomaterial strategy submitted to the lab for physical and chemical attributes, in vitro biological properties, and in vivo compatibility through preclinical toxicology, pharmacology, and efficacy studies.
In addition to preclinical characterization, NCL partners with several pharmaceutical companies for nanotech reformulation and other research and development efforts. Through work under Contractor Cooperative Research and Development Agreements (cCRADAs), the lab has partnered with AstraZeneca and Amgen on reformulation projects and with Pfizer on the characterization of early nanotechnology platforms.
The lab has expertise in formulation and characterization of an extensive variety of nanotechnology-based platforms, including polymeric, lipid-based, dendrimer, and inorganic nanoparticles.
Learn more about NCL and its collaborative opportunities.
- Scientists tackle challenges to save time and money in developing nanomedicines for cancer research
- New nanomedicine strategies provide approach to treat pancreatic cancer
- Understanding the immunogenicity and antigenicity of nanomaterials: Past, present, and future
- FNL scientists discuss important measures to evaluate nanomedicine pharmacokinetics